Interventional Treatment Articles & Analysis: Older
41 news found
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
“With 500 patients across 43 centers, CLOUT is the largest prospective data set ever reported evaluating interventional treatment of DVT,” said Dr. Dexter. “With ClotTriever, we’re now able to completely open the vein, regardless of clot age, and do so safely. ...
From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. ...
EMPOWER CAD will be an extremely valuable study to better inform interventional cardiologists on the optimal treatment strategy for these complex ...
The data was also simultaneously published in EuroIntervention, the official journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). FLASH is a prospective, multicenter, single-arm registry evaluating real-world patient outcomes after treatment of PE with FlowTriever. ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
This alliance with iSTAR Medical is an important step as we continue to be an innovator in glaucoma by maximizing the value of interventional approaches throughout the treatment paradigm. Today’s announcement is validation of the transformational role of MINIject in the treatment of glaucoma, said Michel Vanbrabant, Chief Executive ...
Patient list filtering and list flags enable customized searches of patient lists simplifying workflow for practitioners, and enhanced tools for clinical measurements, treatment planning, and diagnosis. "Today, more than ever, providers continue to face immense pressure to eliminate operating inefficiencies and at the same time enable improved outcomes," said ConcertAI CEO Jeff ...
The Shockwave M5 and S4 IVL Catheters, which are used for the treatment of peripheral arterial calcification lesions, are approved in the United States, the European Union, and other select international jurisdictions and have been used to help treat more than 50,000 patients globally who suffer from peripheral arterial disease. ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with IVL led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous ...
” “As someone who is dedicating her career to addressing the needs of the most complex patients, I find these results very encouraging,” said Katherine Kunkel, MD, MSEd, FSCAI, an interventional cardiologist at Piedmont Heart Institute in Atlanta, Ga., one of the sites that participated in Disrupt CAD III. “Thanks to an increasing focus on the challenges ...
The Shockwave M5+ catheter, which has been in limited launch until today, is specifically designed to decrease IVL treatment time, provide alternative access options, and expand IVL therapy to patients with larger vessel sizes. ...
(Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to ...
Axial Therapeutics was founded based on this research as well as additional preclinical studies to discover and develop new treatments for neurological conditions, including those associated with Autism Spectrum Disorder, Parkinson’s disease, and others. ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention, and treatment, and will improve survival rates for millions of patients worldwide. ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. ...
"Our software solution helps providers in Maryland, in the United States, and in other countries to improve, accelerate, and scale prevention, early intervention, and acute treatment programs. We are saving lives with our clients." ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide. ...
PROPEL Contour is clinically proven to reduce the need for additional interventions (surgical treatments and/or oral steroids) after sinus surgery by 65 percent.1 PROPEL Contour is the third localized drug delivery implant (inclusive of PROPEL and PROPEL Mini), completing the PROPEL family of drug-eluting, bioabsorbable implants now available to ENT specialists ...